Close Menu

NEW YORK (360Dx)  – Citing the technology's ability to detect sepsis in blood samples within hours, H.C. Wainwright today initiated coverage of T2 Biosystems with a Buy rating, and a 12-month price target of $8 for the company's shares.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.